Lung Cancer

Lung Cancer Clinical Trial:

  • PGT307 - OPAXIO™ (paclitaxel poliglumex, CT-2103) in combination with carboplatin for the treatment of chemotherapy-naive advanced non-small cell lung cancer (NSCLC) in women with estradiol greater than 25 pg/mL.
    Learn more about this trial.

What is OPAXIO™? OPAXIO (Oh-packs-ee-oh), formerly known as XYOTAX, is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol®, to a biodegradable polyglutamate polymer, which results in a new chemical entity. Learn more about OPAXIO and other clinical research

Taxol® is a registered trademark of Bristol-Myers Squibb Co.